Eisai Makes Key Decision To Push On With Final Trial For Sepsis Drug
This article was originally published in PharmAsia News
Executive Summary
Eisai said it has decided to push ahead with its Phase III trial for its Eritoran (tetrasodium) drug for treating sepsis following a panel review